Michael Porter's Five Forces model is a framework to study the UK and GCC biotech procurement market. Strategic business managers trying to gain an edge over competing firms in the UK and GCC biotech procurement market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the UK and GCC biotech procurement market have been broken down and analyzed.
PORTER'S FIVE FORCES Analysis: UK and GCC biotech procurement market
Threat of New Entrants
The biotech procurement market in the UK and GCC is experiencing high potential for new entrants due to relatively low barriers to entry in digital, increasing investment in biotech across the region, and government initiatives supporting innovation and healthcare modernization. Particularly in the UAE and Saudi Arabia, ambitious national visions are creating opportunities for startups and tech-driven entrants, intensifying competition and making it easier for agile new players to challenge incumbents.
Bargaining Power of Suppliers
Suppliers in this market such as biotech manufacturers, data providers, and platform technology vendors hold moderate power. While some specialized biotech products may come from a limited number of providers, increasing digitalization and international trade have expanded access to alternative sources. In the GCC, regional efforts to diversify suppliers and encourage local production are balancing the power dynamics, although niche and patented products can still give certain suppliers a strategic advantage.
Threat of Substitutes
The threat of substitutes is high, driven by the availability of alternative procurement methods such as direct purchasing, traditional distributors, or competing digital offering similar services. In addition, broader tech solutions like ERP systems or integrated supply chain may replace the need for specialized biotech procurement, especially if they offer greater scalability or cost-efficiency.
Bargaining Power of Buyers
Buyers, including hospitals, research institutions, and healthcare providers, have high bargaining power due to the increasing number of procurements, rising transparency in pricing, and their ability to switch between service providers. In both the UK and GCC, procurement decisions are heavily influenced by cost-effectiveness and platform reliability, making customer retention difficult and giving buyers strong leverage in negotiations.
Intensity of Rivalry
The biotech procurement platform market is marked by intense rivalry, fueled by rapid technological advancements, increased government and private sector spending in healthcare, and the entrance of global and regional players competing for market share. Both established companies and innovative startups are vying for dominance through pricing strategies, platform features, partnerships, and service quality, creating a highly competitive and fast-evolving landscape.
Financial Analysis of Major Players
Subscription Charges
Based on primary interviews with key stakeholders within the market, it has been identified that the subscription pricing structure for procurement platforms varies significantly based on several critical factors. These factors include the duration of the subscription period, type of account, and the number of users accessing the platform. Typically, billing is conducted on an annual basis, with monthly costs fluctuating in accordance with the user count. Specifically, larger organizations with more extensive user bases tend to benefit from tiered pricing models that reduce per-user costs, whereas smaller organizations may incur higher per-user charges.
Furthermore, it is noteworthy that a considerable segment of UK-based companies adopts alternative pricing strategies, most notably a commission-based model. Under this approach, vendors do not charge upfront subscription fees; instead, they generate revenue through commissions on transactions or procurements facilitated via the platform. This model often aligns incentives towards successful procurement outcomes and may appeal to organizations seeking to minimize fixed costs.
Overall, the market exhibits a diverse landscape of pricing methodologies, influenced by company size, procurement volume, and strategic preferences. The prevalent models include subscription-based pricing, characterized by variable rates depending on usage parameters, and commission-based arrangements, which shift the revenue model from fixed fees to performance-based charges.
SUBSCRIPTION CHARGES BY MAJOR PLAYERS
Company
No. of Users
Average Cost
Amici Procurement
Single User
USD 130 per Month
Multi-Users (For 5 Users)
USD 400 per Month
Prendio LLC
Single User
USD 100 per Month
Multi-Users (For 5 Users)
USD 300 per Month
Quartzy Inc
Single User
USD 50 per Month
Multi-Users (For 5 Users)
USD 200 per Month
Precoro Inc
Single Users/Limited Users
USD 499/999 per Month
Zageno Inc
Single/Multi-Users
1-2% per Transaction Billed
Assay Depot Inc (Scientist.com)
Single/Multi-Users
1-8% per Transaction Billed
Customer Acquisition Cost (CAC)
The Customer Acquisition Cost (CAC) per new customer onboarding onto the biotech platform varies significantly depending on the inclusion of promotional expenditures and the salaries of the sales and marketing teams. To facilitate a comprehensive understanding of these variances, we have compiled a detailed analysis presented in the table below. This table provides the CAC for various prominent biotech procurement platforms, highlighting the factors influencing acquisition costs and enabling informed decision-making for strategic planning and resource allocation.
Customer Acquisition Cost (CAC) for Major Players
Company
Cost Type
Customer Acquisition Cost (CAC)
Amici Procurement
Promotional Cost and Salaries
USD 6,500-8,000
Promotional Cost
USD 2,000
Prendio LLC
Promotional Cost and Salaries
USD 6,000-7,000
Promotional Cost
USD 1,200-1500
Quartzy Inc
Promotional Cost and Salaries
USD 7,000
Promotional Cost
USD 1,500
Precoro Inc
Promotional Cost and Salaries
USD 6,000-6,500
Promotional Cost
USD 1,000-2,000
Zageno Inc
Promotional Cost and Salaries
USD 5,500-6,500
Promotional Cost
USD 1,000
Commission Models for Suppliers
In biotech procurement platforms, commission models for suppliers refer to the ways in which these platforms generate revenue by charging suppliers for their participation or services. Commission models in biotech procurement platforms are designed to align platform revenue with supplier activity, often combining multiple models to optimize monetization while supporting supplier engagement and growth. Common commission models adopted by market players include:
Percentage-Based Commission:
The platform charges suppliers a fixed percentage of each transaction or sale made through the platform. For example, if a supplier sells a biotech product worth US$ 10,000, and the commission rate is 5%, the platform earns US$ 500. Players such as Amici Procurement and Zageno follow percentage-based commission model for suppliers.
Flat Fee per Transaction:
Suppliers pay a predetermined fixed fee for each transaction, regardless of the transaction size. This model provides predictability for both the platform and suppliers.
Subscription-Based Model:
Suppliers pay a recurring subscription fee (monthly, quarterly, or annually) to be listed or to access the platform's services. Additional transaction-based commissions may or may not apply.
Tiered Commission Structures:
Commission rates vary based on sales volume or value. For example, a supplier might pay a lower percentage for higher sales volumes, incentivizing larger transactions.
